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1001. Introduction - chronic obstructive pulmonary disease
Chronic obstructive pulmonary disease (COPD) is a common pre-
ventable and treatable disease that is characterized by persistent respi-






en access article undalveolar abnormalities usually caused by signiﬁcant exposure to nox-
ious particles or gasses (GOLD, 2017). COPD is the third leading cause
of death worldwide (Lozano et al., 2012).
COPD is an umbrella term for airﬂow limitation due to parenchymal
destruction (emphysema) and (small) airways disease with inﬂamma-
tion and ﬁbrosis. The relative contribution of airway disease, parenchy-
mal destruction and other changes vary fromperson to person and even
between lung lobes. This results in multiple different phenotypes (Han
et al., 2010; Lopez-Campos, Bustamante, Munoz, & Barreiro, 2014;
Pinto et al., 2015; Postma, Weiss, van den Berge, Kerstjens, &
Koppelman, 2015), most distinctly chronic bronchitis and emphysema.
Episodes with worsening of respiratory symptoms and anxiety, exacer-
bations, further contribute to the decrease in quality of life and survivaler the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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inﬂation and usually require additional therapy (Lopez-Campos &
Agusti, 2015; van Geffen, Douma, Slebos, & Kerstjens, 2016).
2. Pathophysiology
2.1. Bronchus obstruction
COPD is characterized by a chronic airﬂow obstruction. This can be
detected with spirometry. The spirometry then shows a decreased
forced expiratory ﬂow in 1 s (FEV1) and a reduced ratio between the
FEV1 and the forced vital capacity (FVC).
Bronchus obstruction and inﬂammation were the ﬁrst factors to be
treated in COPD. Bronchus obstruction was treated with bronchodila-
tors and inﬂammation was treated with ﬁrst oral corticosteroids and
later inhaled corticosteroids. (GOLD, 2017; Hogg et al., 2004).
2.2. Hyperinﬂation
Hyperinﬂation is entrapment of air in the lungs during expiration,
causing the lungs to hyperinﬂate. Hyperinﬂation is caused by bronchus
obstruction. This phenomenon is frequently present in COPD, both in
stable state, during exercise, and during exacerbations (Mahler &
O'Donnell, 2015; O'Donnell & Laveneziana, 2006; van Geffen, Slebos, &
Kerstjens, 2015). Hyperinﬂation causes symptoms such as increased
dyspnea and limited exercise capacity due to a decreased inspiratory ca-
pacity (IC), increased functional residual capacity (FRC) and increased
residual volume (RV). These changes in lung volumes are accompanied
by a decrease in FEV1 in most hyperinﬂated COPD patients (Fig. 1)
(O'Donnell & Laveneziana, 2007). Hyperinﬂation usually has an impor-
tant dynamic component, since during exercise, hyperinﬂation in-
creases further (Cooper, 2006; Guenette, Webb, & O'Donnell, 2012).
Hyperinﬂation is a predictor of mortality in stable state (Moore et al.,
2010).
2.3. Gas exchange limitations
Themain gasses to be inﬂuenced in COPD are oxygen and carbon di-
oxide. These gasses are important for themetabolism of all living cells of
the human body. Abnormalities in their transfer can result inFig. 1. Schematic volume time curve showing change in lung volumes in hyperinﬂated
COPD patients. Arrows indicate the direction changes. IC: inspiratory capacity; FRC:
functional residual capacity; RV: residual volume; TLC: total lung capacity.hypercapnia and hypoxia in COPD. Gas transfer is inﬂuenced by the en-
trance of gasses in the alveoli, by the pulmonary vascular system and
their ratio (ventilation/perfusion ratio). Additionally, the number of al-
veoli, the amount of haemoglobin in the blood and the membrane sep-
arating air and blood in the alveoli are all inﬂuencing gas exchange
(Elbehairy et al., 2015; GOLD, 2017; Rodriguez-Roisin et al., 2009).
Speciﬁc treatmentmainly aimed to inﬂuence the gas exchange is not
in common use. Long-term oxygen does not provide symptom or sur-
vival beneﬁt (“A Randomized Trial of Long-Term Oxygen for COPD
with Moderate Desaturation, 2016”). Thus far it is not possible to recre-
ate destroyed alveoli. Stem cells, originating from the embryonic meso-
derm although seem safe to administer. However, thus far they didn't
improved gas exchange but where used for their antiinﬂammatory ef-
fects (Weiss, Casaburi, Flannery, LeRoux-Williams, & Tashkin, 2013).
Vasodilators do not improve and may even worsen gas exchange
(Barbera et al., 1996; Blanco et al., 2013; GOLD, 2017).
3. Pharmacological treatment
Bronchodilators are the cornerstone of therapy for stable COPD. Two
major classes of bronchodilators are advocated in guidelines, β2-ago-
nists and muscarinic antagonists. Bronchodilators are mainly adminis-
tered via inhalers, most commonly by pressurized metered-dose
inhalers or dry powder inhalers (Global Initiative for Chronic
Obstructive, 2016). The ﬁrst substances worked for a short period of
time and are therefore called short acting bronchodilators. Long acting
bronchodilators are especially useful in treating hyperinﬂation
(O'Donnell, Lam, & Webb, 1999). Their beneﬁt however is still limited.
Their effects are most commonly measured via changes in FEV1. The
most commonly accepted minimal clinical important difference for
FEV1 is 100 ml. The median increase in trough FEV1 in COPD patients
treated with LABA is 99 ml. For LAMA this is a median change of
104 ml (Kew, Dias, & Cates, 2014). When LAMA are combined with a
LABA, the FEV1 increases further by 60 ml (Farne & Cates, 2015).
Quality of life in COPD is most commonly measured via the St
George's Respiratory Questionnaire (SGRQ). The minimal clinical im-
portant difference for regular COPD patients difference is considered
to be four (Jones et al., 2014). LABA show an improvement in SGRQ of
2.29 points; LAMA with 2.63 points. When LAMA are combined with a
LABA the SGQR improves further by 1.34 points (Farne & Cates, 2015).
Although lung rehabilitation should not be perceived as pharmacologi-
cal treatment and does not primarily aim to improve FEV1, it is a very
important treatment for COPD patients. Lung rehabilitation improves
quality of life measured by SGRQ with 6.89 points (McCarthy et al.,
2015). Inhaled corticosteroids in COPD are aimed to reduce airway in-
ﬂammation. Treatmentwith inhaled corticosteroids alone does not con-
clusivelymodify long-term decline of FEV1 ormortality in COPD (GOLD,
2017; Yang, Clarke, Sim, & Fong, 2012).
With the perception that hyperinﬂation is an important contributor
to symptoms and tomorbidity, came the idea that targeted treatment of
hyperinﬂation is an important goal and therefore a treatable trait. Hy-
perinﬂation can be reduced with long-acting bronchodilators, and the
following personalized non-pharmacological strategies have been
shown to be able to reduce hyperinﬂation and improve dyspnea: reha-
bilitation programs, non-invasive ventilation, cognitive-behavioural
strategies, and speciﬁc lung volume reduction interventions (Cooper,
2006; Mahler & O'Donnell, 2015).
4. Lung volume reduction surgery
The ﬁrst lung volume reduction was performed by surgery, and al-
ready as early as 1957 (Brantigan & Mueller, 1957). As the name sug-
gests, lung volume reduction surgery (LVRS) reduces lung volume, by
removing the most destructed and hyperinﬂated part of the lung
(Criner et al., 1999; Geddes et al., 2000). LVRS can be done unilaterally
and bilaterally. Reduction of the volume of hyperinﬂated COPD patients
98 W.H. van Geffen et al. / Pharmacology & Therapeutics 179 (2017) 96–101reduces exertional breathlessness at a givenworkload. This is attributed
to a combination of reduced thoracic hyperinﬂation, reduced breathing
frequency, and reduced mechanical constraints on lung volume expan-
sion (O'Donnell, Webb, Bertley, Chau, & Conlan, 1996; van Geffen &
Slebos, 2015). The largest surgical lung volume reduction trial (The
‘NETT trial’) assessed 1218 patients with severe emphysema who
underwent pulmonary rehabilitation (Fishman et al., 2003). These pa-
tients were randomly assigned to undergo lung volume reduction sur-
gery or to receive continued medical treatment only. The trial showed
no survival advantage for surgery over medical therapy. The highly in-
vasive surgical technique was associated with increased morbidity and
mortality, especially in patients with either a FEV1 or diffusion capacity
below 20% of predicted, and in patients treated in the lower lobes of the
lung. A subgroup analysis showed a survival advantage for patientswith
both predominantly upper-lobe emphysema and lowbase-line exercise
capacity. These results severely limit the applicability of LVRS. These re-
sults also led to creative new approaches such as full lobar resections by
VATS and so called “non-cutting” techniques, both aiming at reducing
postsurgical prolonged air leak complications (Beckers et al., 2016;
Pompeo, Tacconi, & Mineo, 2011).
5. Bronchoscopic treatments
Since the NETT trial and its ambiguous results, much less invasive
bronchoscopic treatment options for achieving lung volume reduction
in patients with the predominantly emphysema disease phenotype
have been developed, aimed at improving quality of life and reduction
of mortality and morbidity both by deﬂation itself, whilst evading
much of the mortality and morbidity associated with surgery
(Fishman et al., 2003; Shah, Herth, van Geffen, Deslee, & Slebos, 2017).
Different technologies have been tested, with most of them still being
performed in clinical trials only, though some of them have already
made it in into clinical practice in some European countries (Shah et
al., 2017). Due to the different mechanisms of action of the different
bronchoscopic treatments it is important to carefully phenotype pa-
tients who might beneﬁt from each bronchoscopic treatment. We will
discuss the different technologies separately.
5.1. Endobronchial stents
Airway bypass is a bronchoscopic treatmentwhereby transbronchial
passages through thewalls of themore central airways into the lung pa-
renchyma are created to release trapped air. These passages are sup-
ported with paclitaxel drug eluting stents to facilitate the mechanics
of breathing with an aim of lung volume reduction.
This technology was tested in a multicenter randomized, double-
blind, full sham bronchoscopy controlled trial, the EASE trial (Shah et
al., 2011). 208 patients were treated and the control group consisted
of 107 patients. Patients with severe hyperinﬂation were included
(FEV1 below 50% predicted or 1 l, RV N 180% predicted). All patients
had pulmonary rehabilitation before the procedure. Although the pa-
tients improved considerably initially after theprocedure, the trial failed
to show any longer lasting superiority of airway bypass for the primary
endpoints (FVC and mMRC) and FEV1. Also quality of life measured by
the SGRQ nor the 6-minute walk test showed a lasting beneﬁt for the
patients treatedwith this technique. It is noteworthy that the sham con-
trol patients did not show any placebo effect on SGRQ. The therapy
failed because themajority of the airway stents showed no (lasting) pa-
tency due to either obstruction bymucus, ﬁbrotic tissue, the next bullae,
or simply dislocated.
5.2. Valves
One-way endobronchial and intrabronchial valves are devices de-
signed to prevent air from ﬂowing into the most damaged lobe of the
lungs. Whilst prevented to enter the lobe, air is able to exit the lobethus creating a resorption atelectasis of the target lobe. This atelectasis
causes lung volume reduction and thus reduces hyperinﬂation. The
ﬁrst randomized trial assessing endobronchial valves in 2010 showed
only a relatively small beneﬁt in favour of the valves (Sciurba et al.,
2010). Included patients all had heterogeneous emphysema, a predict-
ed FEV1 between 15 and 45% and a residual volume of N150% predicted.
Post hoc analysis of this trial, and the results of the European part of the
VENT trial showed big differences between responders and non-re-
sponders (Herth et al., 2012). A better response was associated with a
complete ﬁssure on the chest CT scan, and a complete occlusion of the
lobe. Recently, a single center, sham controlled RCT showed that when
the completeness of theﬁssure is deemed present assessed onHRCT be-
fore the procedure, the responder rates increase and a signiﬁcant bene-
ﬁt in symptoms and FEV1 ensues (Davey et al., 2015). Exacerbations and
pneumothoraces were increased in the treated group, and two patients
in the treatment arm died during follow-up.
The Stelvio study also included patients which complete ﬁssures on
the HRCT (Klooster et al., 2015). The completeness of the ﬁssure in the
target lobewas conﬁrmed with an actual measurement of the collateral
ﬂow by the Chartis system during bronchoscopy. The use of this system
resulted in an even better responder rate in the treated patients than
preceding studies. The Stelvio trial included patients with both hetero-
geneous and homogenous emphysema. The patients showed an in-
crease in FEV1 of 140 ml compared with placebo on top of maximum
bronchus dilatation. Their quality of life measured by the SGRQ im-
proved with 14.7 points compared with placebo.
After post-hoc data using endobronchial valves showed promise in
treating homogeneous emphysema patients, a group that has no surgi-
cal alternative, the Impact trial was designed to prospectively assess the
usefulness of endobronchial valve treatment in patients with homoge-
nous emphysema (Valipour et al., 2016). The results conﬁrmed the ear-
lier found beneﬁcial effect of the endobronchial valves. The most
common adverse events in this trial were pneumothoraces (26%) and
exacerbations of COPD requiring hospitalization (16%). An advantage
of this therapy is that valves can be removed if patients do not beneﬁt
from the treatment.
The trials testing intrabronchial valves in patients with occlusion of
the whole target lobe in patients with complete ﬁssures are currently
awaited. An earlier trial treating patients without complete occlusion
did not show results comparable with the endobronchial valves yet
(Eberhardt, Gompelmann, Schuhmann, Heussel, & Herth, 2012;
Ninane et al., 2012; Wood et al., 2014).
5.3. Endobronchial coils
Endobronchial coils are shape-memory nitinol devices delivered
bronchoscopically into the airways. They induce lung volume reduction
by contraction of lung parenchyma. Patients are most commonly treat-
ed bilaterally with a total of approximately 11 coils per lung. The ﬁrst
pilot studies with this technique were published in 2010 and 2012
(Herth, Eberhard, Gompelmann, Slebos, & Ernst, 2010; Slebos,
Klooster, Ernst, Herth, & Kerstjens, 2012). Since then the technique
has been tested in several randomized controlled trials and coils are
nowused commercially in some European countries. Three randomized
controlled trials have been published with a total of 231 patients in the
treated group and 230 in the standard medical care group (Deslee et al.,
2016; Sciurba et al., 2016; Shah et al., 2013). Those treated with coils
showed an improvement in 6-min walk distance, FEV1 and symptoms
measured by SGRQ compared with the patients who received standard
care. The largest of these trials, the RENEW trial showed an improve-
ment in FEV1 in patients treated bilaterally of 130 ml from baseline,
they did not report a between group difference in millilitres, SGRQ im-
proved with 8,9 points after 6 months compared with placebo
(Sciurba et al., 2016). The REVOLENS trial reported a difference of
90 ml between the treatment and placebo group (Deslee et al., 2016)
on top of maximum bronchus dilatation. Treatment was associated
Fig. 2. Effect sizes of different therapeutic options in COPD on quality of life as measured
with the SGRQ. Y axis: Improvement in SGRQ in points. X axis Different therapeutic
options. LABA: long acting beta-2-agonists, LAMA: long acting muscarinic antagonists.
Effect size for LABA/LAMA is the additional effect when a LAMA is combined with a
LABA. Effect sizes for rehabilitation, valves and coils are on top of maximum
bronchodilation. Compiled from the following references: (Farne & Cates, 2015; Kew et
al., 2014; Klooster et al., 2015; McCarthy et al., 2015; Sciurba et al., 2016).
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nia (20%) and pneumothorax (10%). Once placed, endobronchial coils
cannot be removed (Sciurba et al., 2016).
5.4. Sclerosing agents
Two different techniques aimed at sclerosing the most the diseased
part of the lung have been tested. The sclerosis causes a lung volume re-
duction effect in the treated part of the lung. The results of the tech-
niques are irreversible (Shah et al., 2017).
The ﬁrst technique is known as bronchoscopic thermal vapour abla-
tion. This technology works by locally applying steam to induce a per-
manent ﬁbrosis and atelectasis. The Step-up trial randomized patients
with upper lobe predominant emphysema only. A total of 46 patients
was randomized to vapour therapy and 24 to standard care (Herth et
al., 2016). Treated patients improved in FEV1 (11% at 6 months), quality
of life (9.7 points in SGRQat 6month) and exercise capacity (31m in the
6minutewalk test comparedwith the untreated group). Themost com-
mon side effects were an increased rate of exacerbations and pneumo-
nitis in the treated patients.
The second technique uses a lung sealant called Aeriseal. This is a so-
lution mixed by air which is delivered by bronchoscope at a diseased
part of the lung. The techniquewasﬁrst published in 2009 andwas test-
ed with an aim of lung volume reduction in advanced, upper lobe pre-
dominant emphysema (Criner et al., 2009; Herth et al., 2011).
The Aspire trial is the only randomized trial assessing this technique,
however the sponsor ran out of ﬁnancial resources and therefore the
trial was terminated prematurely. Data from the trial has been pub-
lished for a follow-up period up to 6 month (Come et al., 2015). The
few patients who were treated showed an increased response rate in
FEV1, symptoms and 6minutewalk test. The lownumbers in the treated
patient group diminished further by 2 deaths and over 40% of the pa-
tients had to be admitted at the hospital with serious adverse events
due to severe inﬂammatory responses. Because of its great potential to
speciﬁcally target interlobar emphysematous areas, its use has been
redeﬁned and efforts are underway to more carefully use this device
using slowly increasing dosages and repeat bronchoscopies. (NCT
02877459).
5.5. Targeted lung denervation
In 2015 a pilot study performed in South Africa and the Netherlands
was performedwith a system to elicit targeted lung denervation (Slebos
et al., 2015). This system is designed to disrupt parasympathetic pulmo-
nary nerves surrounding themain bronchi using a special RF-energy re-
leasing system, thereby decreasing the release of acetylcholine in the
airways, resulting in a permanent anti-cholinergic effect. Twenty-two
patients were treated, showing feasibility of the intervention. The trail
showed a better outcomes for the highest RF energy dose used. One
year changes from baseline in the 20 W dose compared to the 15 W
dose were: FEV1 (+11.6% ± 32.3 vs +0.02% ± 15.1, p = 0.324), sub-
maximal cycle endurance (+6.8 min ± 12.8 vs 2.6 min ± 8.7, p =
0.277), and St George's Respiratory Questionnaire (−11.1 points ±
9.1 vs −0.9 points ± 8.6, p = 0.044). The adverse event analysis
showed that 59% of the patients developed a COPD exacerbation in
the ﬁrst year. The ﬁrst randomized sham controlled trial assessing this
technology is currently underway (ClinicalTrials.gov identiﬁer:
NCT02058459).
5.6. Liquid nitrogen metered cryospray
Liquid Nitrogen Metered Cryospray is a method designed to
bronchoscopically deliver liquid nitrogen to the central airways in
such a way that is leads to a cryoablation depth of 0.1 to 0.5 mm for
the treatment of chronic bronchitis. This treatment is intended to induce
a regenerative airway tissue healing effect, by initially destroying thehyperplastic goblet cells and excess submucous glands by cryo necrosis.
After treatment rapid rejuvenation of normal epithelium occurs, with-
out scarring occurs, a hallmark of cryoablation, and it is thus a potential
future treatment for chronic bronchitis (Coad & Bischof, 2003; Godwin
& Coad, 2009). The ﬁrst in human trials testing this system and its hy-
pothesis are currently underway (NCT02106143, NCT02483052, and
NCT02483637).
6. Concluding remarks
Different emerging bronchoscopic treatments for COPD have been
tested recently, most of them with an aim of lung volume reduction in
hyperinﬂated emphysema patients. Most of the evidence has been col-
lected for the use of endobronchial valves and endobronchial coils. In
highly selected patients these therapies do show beneﬁt both in quality
of life (Fig. 2), and in lung function (Fig. 3).
Although the bronchoscopic procedures can be regarded as mini-
mally invasive, serious adverse events have been observed. The occur-
rence of pneumothoraxes, especially with successful valve placement,
and increase in infectious and inﬂammatory events when using coils
probably being the most important.
More research is need to better select the patients who will beneﬁt
from the different treatments. Also additional research is needed to bet-
ter predict and treat the procedure related adverse events. More thera-
pies are being developed and the existing are being developed further.
The fast development of these bronchoscopic treatments will extend
the therapeutic arsenal of the respiratory physician for patients with
COPD.
Conﬂict of interest statement
WG: received an European Respiratory Society Fellowship STRTF
2016, and reports a grant from Novartis to the institution for an investi-
gator-initiated trial both outside of the submittedwork HK: reports fees
paid to his institution based on advisory board participation, lectures,
and per patient recruited in trials from AstraZeneca/Almirall,
Boehringer Ingelheim, Chiesi, GSK, Novartis, Pﬁzer, Takeda, TEVA,
PneumRx/BTG, Holaira, Pulmonx, Boston Scientiﬁc and Olympus DJS re-
ports grants, personal fees, non-ﬁnancial support and others from
PneumRx/BTG, CA, USA, grants, personal fees, non-ﬁnancial support
and other from Boston Scientiﬁc, Europe/USA, grants and non-ﬁnancial
support from Aeris Therapeutics, USA, grants, personal fees, non-ﬁnan-
cial support and other from Holaira, Inc. MN, USA, personal fees from
Fig. 3. Effect sizes of different therapeutic options in COPDwith FEV1. Y axis: Improvement
in FEV1 in millilitres. X axis Different therapeutic options. LABA: long acting beta-2-
agonists, LAMA: long acting muscarinic antagonists. Effect size for LABA/LAMA is the
additional effect when a LAMA is combined with a LABA. Effect sizes for valves and coils
are on top of maximum bronchodilation. Compiled from the following references:
(Deslee et al., 2016; Farne & Cates, 2015; Kew et al., 2014; Klooster et al., 2015).
100 W.H. van Geffen et al. / Pharmacology & Therapeutics 179 (2017) 96–101Olympus Europe, Germany, grants, personal fees, non-ﬁnancial support
and other from PulmonX, CA, USA.References
A Randomized Trial of Long-Term Oxygen for COPD with Moderate Desaturation (2016).
The New England Journal of Medicine 375, 1617–1627.
Barbera, J. A., Roger, N., Roca, J., Rovira, I., Higenbottam, T. W., & Rodriguez-Roisin, R.
(1996).Worsening of pulmonary gas exchangewith nitric oxide inhalation in chronic
obstructive pulmonary disease. Lancet 347, 436–440.
Beckers, F., Lange, N., Koryllos, A., Picchioni, F., Windisch, W., & Stoelben, E. (2016). Uni-
lateral lobe resection by video-assisted thoracoscopy leads to the most optimal func-
tional improvement in severe emphysema. The Thoracic and Cardiovascular Surgeon
64, 336–342.
Blanco, I., Santos, S., Gea, J., Guell, R., Torres, F., Gimeno-Santos, E., ... Barbera, J. A. (2013).
Sildenaﬁl to improve respiratory rehabilitation outcomes in COPD: A controlled trial.
The European Respiratory Journal 42, 982–992.
Brantigan, O. C., & Mueller (1957). Surgical treatment of pulmonary emphysema. The
American Surgeon 23, 789–804.
Coad, J. E., & Bischof, J. C. (2003). Histologic differences between cryothermic and hyperther-
mic therapiesVol. 4954. (pp. 27–36), 27–36.
Come, C. E., Kramer, M. R., Dransﬁeld, M. T., Abu-Hijleh, M., Berkowitz, D., Bezzi, M., ...
Washko, G. R. (2015). A randomised trial of lung sealant versus medical therapy for
advanced emphysema. The European Respiratory Journal 46, 651–662.
Cooper, C. B. (2006). The connection between chronic obstructive pulmonary disease
symptoms and hyperinﬂation and its impact on exercise and function. The
American Journal of Medicine 119, 21–31.
Criner, G. J., Cordova, F. C., Furukawa, S., Kuzma, A. M., Travaline, J. M., Leyenson, V., &
O'Brien, G. M. (1999). Prospective randomized trial comparing bilateral lung volume
reduction surgery to pulmonary rehabilitation in severe chronic obstructive pulmo-
nary disease. American Journal of Respiratory and Critical Care Medicine 160,
2018–2027.
Criner, G. J., Pinto-Plata, V., Strange, C., Dransﬁeld, M., Gotfried, M., Leeds, W., ... Celli, B.
(2009). Biologic lung volume reduction in advanced upper lobe emphysema: Phase
2 results. American Journal of Respiratory and Critical Care Medicine 179, 791–798.
Davey, C., Zoumot, Z., Jordan, S., McNulty,W. H., Carr, D. H., Hind, M. D., ... Hopkinson, N. S.
(2015). Bronchoscopic lung volume reduction with endobronchial valves for patients
with heterogeneous emphysema and intact interlobar ﬁssures (the BeLieVeR-HIFi
study): A randomised controlled trial. Lancet 386, 1066–1073.
Deslee, G., Mal, H., Dutau, H., Bourdin, A., Vergnon, J. M., Pison, C., ... Marquette, C. H.
(2016). Lung volume reduction coil treatment vs usual care in patients with severe
emphysema: The REVOLENS randomized clinical trial. JAMA 315, 175–184.
Eberhardt, R., Gompelmann, D., Schuhmann, M., Heussel, C. P., & Herth, F. J. (2012). Com-
plete unilateral vs partial bilateral endoscopic lung volume reduction in patients with
bilateral lung emphysema. Chest 142, 900–908.
Elbehairy, A. F., Ciavaglia, C. E., Webb, K. A., Guenette, J. A., Jensen, D., Mourad, S. M., ...
Canadian Respiratory Research, N. (2015). Pulmonary gas exchange abnormalities
inmild chronic obstructive pulmonary disease. Implications for dyspnea and exercise
intolerance. American Journal of Respiratory and Critical Care Medicine 191,
1384–1394.
Farne, H. A., & Cates, C. J. (2015). Long-acting beta2-agonist in addition to tiotropium ver-
sus either tiotropium or long-acting beta2-agonist alone for chronic obstructive pul-
monary disease. Cochrane Database of Systematic Reviews, CD008989.
Fishman, A., Martinez, F., Naunheim, K., Piantadosi, S., Wise, R., Ries, A., ... Wood, D. E.
(2003). A randomized trial comparing lung-volume-reduction surgery with medicaltherapy for severe emphysema. The New England Journal of Medicine 348, 2059–2073.
Geddes, D., Davies, M., Koyama, H., Hansell, D., Pastorino, U., Pepper, J., ... Goldstraw, P.
(2000). Effect of lung-volume-reduction surgery in patients with severe emphysema.
The New England Journal of Medicine 343, 239–245.
Global Initiative for Chronic Obstructive, L. D (2016). From the global strategy for the diag-
nosis, management and prevention of COPD, global initiative for chronic obstructive lung
disease (GOLD) 2016. (In GOLD).
Godwin, B. L., & Coad, J. E. (2009). Healing responses following cryothermic and hyperther-
mic tissue ablationVol. 7181. (pp. 718103–718109), 718103–718109.
GOLD (2017). Global strategy for the diagnosis, management, and prevention of chronic ob-
structive pulmonary disease 2017 report. Global initiative for chronic obstructive lung
disease.
Guenette, J. A., Webb, K. A., & O'Donnell, D. E. (2012). Does dynamic hyperinﬂation con-
tribute to dyspnoea during exercise in patients with COPD? The European
Respiratory Journal 40, 322–329.
Han, M. K., Agusti, A., Calverley, P. M., Celli, B. R., Criner, G., Curtis, J. L., ... Martinez, F. J.
(2010). Chronic obstructive pulmonary disease phenotypes: The future of COPD.
American Journal of Respiratory and Critical Care Medicine 182, 598–604.
Herth, F. J., Eberhard, R., Gompelmann, D., Slebos, D. J., & Ernst, A. (2010). Bronchoscopic
lung volume reduction with a dedicated coil: A clinical pilot study. Therapeutic
Advances in Respiratory Disease 4, 225–231.
Herth, F. J., Gompelmann, D., Stanzel, F., Bonnet, R., Behr, J., Schmidt, B., ... Eberhardt, R.
(2011). Treatment of advanced emphysema with emphysematous lung sealant
(AeriSeal(R)). Respiration 82, 36–45.
Herth, F. J., Noppen, M., Valipour, A., Leroy, S., Vergnon, J. M., Ficker, J. H., ... Ernst, A.
(2012). Efﬁcacy predictors of lung volume reduction with Zephyr valves in a Europe-
an cohort. The European Respiratory Journal 39, 1334–1342.
Herth, F. J., Valipour, A., Shah, P. L., Eberhardt, R., Grah, C., Egan, J., ... Gompelmann, D.
(2016). Segmental volume reduction using thermal vapour ablation in patients
with severe emphysema: 6-month results of the multicentre, parallel-group, open-
label, randomised controlled STEP-UP trial. The Lancet Respiratory Medicine 4,
185–193.
Hogg, J. C., Chu, F., Utokaparch, S., Woods, R., Elliott, W. M., Buzatu, L., ... Pare, P. D. (2004).
The nature of small-airway obstruction in chronic obstructive pulmonary disease. The
New England Journal of Medicine 350, 2645–2653.
Jones, P. W., Beeh, K. M., Chapman, K. R., Decramer, M., Mahler, D. A., & Wedzicha, J. A.
(2014). Minimal clinically important differences in pharmacological trials. American
Journal of Respiratory and Critical Care Medicine 189, 250–255.
Kew, K. M., Dias, S., & Cates, C. J. (2014). Long-acting inhaled therapy (beta-agonists, an-
ticholinergics and steroids) for COPD: A networkmeta-analysis. Cochrane Database of
Systematic Reviews, CD010844.
Klooster, K., Ten Hacken, N. H., Hartman, J. E., Kerstjens, H. A., van Rikxoort, E. M., & Slebos,
D. J. (2015). Endobronchial valves for emphysema without interlobar collateral ven-
tilation. The New England Journal of Medicine 373, 2325–2335.
Lopez-Campos, J. L., & Agusti, A. (2015). Heterogeneity of chronic obstructive pulmonary
disease exacerbations: A two-axes classiﬁcation proposal. The Lancet Respiratory
Medicine 3, 729–734.
Lopez-Campos, J. L., Bustamante, V., Munoz, X., & Barreiro, E. (2014). Moving towards pa-
tient-centered medicine for COPD management: Multidimensional approaches ver-
sus phenotype-based medicine–A critical view. COPD 11, 591–602.
Lozano, R., Naghavi, M., Foreman, K., Lim, S., Shibuya, K., Aboyans, V., ... Memish, Z. A.
(2012). Global and regional mortality from 235 causes of death for 20 age groups
in 1990 and 2010: A systematic analysis for the Global Burden of Disease Study
2010. Lancet 380, 2095–2128.
Mahler, D. A., & O'Donnell, D. E. (2015). Recent advances in dyspnea. Chest 147, 232–241.
McCarthy, B., Casey, D., Devane, D., Murphy, K., Murphy, E., & Lacasse, Y. (2015). Pulmo-
nary rehabilitation for chronic obstructive pulmonary disease. Cochrane Database of
Systematic Reviews, CD003793.
Moore, A. J., Soler, R. S., Cetti, E. J., Amanda Sathyapala, S., Hopkinson, N. S., Roughton, M.,
... Polkey, M. I. (2010). Sniff nasal inspiratory pressure versus IC/TLC ratio as predic-
tors of mortality in COPD. Respiratory Medicine 104, 1319–1325.
Ninane, V., Geltner, C., Bezzi, M., Foccoli, P., Gottlieb, J., Welte, T., ... Gonzalez, X. (2012).
Multicentre European study for the treatment of advanced emphysema with bron-
chial valves. The European Respiratory Journal 39, 1319–1325.
O'Donnell, D. E., Lam, M., & Webb, K. A. (1999). Spirometric correlates of improvement in
exercise performance after anticholinergic therapy in chronic obstructive pulmonary
disease. American Journal of Respiratory and Critical Care Medicine 160, 542–549.
O'Donnell, D. E., & Laveneziana, P. (2006). The clinical importance of dynamic lung hyper-
inﬂation in COPD. COPD 3, 219–232.
O'Donnell, D. E., & Laveneziana, P. (2007). Dyspnea and activity limitation in COPD: Me-
chanical factors. COPD 4, 225–236.
O'Donnell, D. E., Webb, K. A., Bertley, J. C., Chau, L. K., & Conlan, A. A. (1996). Mechanisms
of relief of exertional breathlessness following unilateral bullectomy and lung volume
reduction surgery in emphysema. Chest 110, 18–27.
Pinto, L. M., Alghamdi, M., Benedetti, A., Zaihra, T., Landry, T., & Bourbeau, J. (2015). Der-
ivation and validation of clinical phenotypes for COPD: A systematic review.
Respiratory Research 16, 50.
Pompeo, E., Tacconi, F., & Mineo, T. C. (2011). Comparative results of non-resectional lung
volume reduction performed by awake or non-awake anesthesia. European Journal of
Cardio-Thoracic Surgery 39, e51–e58.
Postma, D. S., Weiss, S. T., van den Berge, M., Kerstjens, H. A., & Koppelman, G. H. (2015).
Revisiting the Dutch hypothesis. The Journal of Allergy and Clinical Immunology 136,
521–529.
Rodriguez-Roisin, R., Drakulovic, M., Rodriguez, D. A., Roca, J., Barbera, J. A., & Wagner, P.
D. (2009). Ventilation-perfusion imbalance and chronic obstructive pulmonary dis-
ease staging severity. Journal of Applied Physiology 106(1985), 1902–1908.
101W.H. van Geffen et al. / Pharmacology & Therapeutics 179 (2017) 96–101Sciurba, F. C., Criner, G. J., Strange, C., Shah, P. L., Michaud, G., Connolly, T. A., ... Slebos, D. J.
(2016). Effect of endobronchial coils vs usual care on exercise tolerance in patients
with severe emphysema: The RENEW randomized clinical trial. JAMA 315(20),
2178–2189. http://dx.doi.org/10.1001/jama.2016.6261.
Sciurba, F. C., Ernst, A., Herth, F. J., Strange, C., Criner, G. J., Marquette, C. H., ... McLennan, G.
(2010). A randomized study of endobronchial valves for advanced emphysema. The
New England Journal of Medicine 363, 1233–1244.
Shah, P. L., Herth, F. J., van Geffen, W. H., Deslee, G., & Slebos, D. J. (2017). Lung volume
reduction for emphysema. The Lancet Respiratory Medicine 5(2), 147–156. http://dx.
doi.org/10.1016/S2213-2600(16)30221-1.
Shah, P. L., Slebos, D. J., Cardoso, P. F., Cetti, E., Voelker, K., Levine, B., ... Sybrecht, G. W.
(2011). Bronchoscopic lung-volume reduction with exhale airway stents for emphy-
sema (EASE trial): Randomised, sham-controlled, multicentre trial. Lancet 378,
997–1005.
Shah, P. L., Zoumot, Z., Singh, S., Bicknell, S. R., Ross, E. T., Quiring, J., ... Kemp, S. V. (2013).
Endobronchial coils for the treatment of severe emphysema with hyperinﬂation
(RESET): A randomised controlled trial. The Lancet Respiratory Medicine 1, 233–240.
Slebos, D. J., Klooster, K., Ernst, A., Herth, F. J., & Kerstjens, H. A. (2012). Bronchoscopic lung
volume reduction coil treatment of patients with severe heterogeneous emphysema.
Chest 142, 574–582.
Slebos, D. J., Klooster, K., Koegelenberg, C. F., Theron, J., Styen, D., Valipour, A., ... Bolliger, C.
T. (2015). Targeted lung denervation for moderate to severe COPD: a pilot study.
Thorax 70, 411–419.Valipour, A., Slebos, D. J., Herth, F., Darwiche, K., Wagner, M., Ficker, J. H., ... Team, I. S.
(2016). Endobronchial valve therapy in patients with homogeneous emphysema: Re-
sults from the IMPACT study. American Journal of Respiratory and Critical Care
Medicine.
van Geffen, W. H., Douma, W. R., Slebos, D. J., & Kerstjens, H. A. (2016). Bronchodilators
delivered by nebuliser versus pMDI with spacer or DPI for exacerbations of COPD.
Cochrane Database of Systematic Reviews, CD011826.
van Geffen, W. H., & Slebos, D. J. (2015). Autobullectomy in patients with COPD.
Respiration 89, 88.
van Geffen, W. H., Slebos, D. J., & Kerstjens, H. A. (2015). Hyperinﬂation in COPD exacer-
bations. The Lancet Respiratory Medicine 3, e43–e44.
Weiss, D. J., Casaburi, R., Flannery, R., LeRoux-Williams, M., & Tashkin, D. P. (2013). A pla-
cebo-controlled, randomized trial of mesenchymal stem cells in COPD. Chest 143,
1590–1598.
Wood, D. E., Nader, D. A., Springmeyer, S. C., Elstad, M. R., Coxson, H. O., Chan, A., ... Team, I.
B. V. V. T. R. (2014). The IBV valve trial: A multicenter, randomized, double-blind trial
of endobronchial therapy for severe emphysema. Journal of Bronchology &
Interventional Pulmonology 21, 288–297.
Yang, I. A., Clarke, M. S., Sim, E. H., & Fong, K. M. (2012). Inhaled corticosteroids for stable
chronic obstructive pulmonary disease. Cochrane Database of Systematic Reviews,
CD002991.
